Post-earnings recap
Reported
Thu, Feb 25, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Moderna's earnings report showed a significant EPS miss, which reflects the challenges the company is facing in the current market. Despite this, the stock rose by 2.48%, likely due to investor optimism about the company's ongoing vaccine efforts and potential future growth. The lack of revenue guidance may leave some investors cautious about the company's short-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -174.90% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future earnings due to uncertainties in vaccine distribution. They emphasized their commitment to research and development.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on its ongoing vaccine development efforts.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—